The vaccine-site microenvironment induced by injection of incomplete freund's adjuvant, with or without melanoma peptides

Journal of Immunotherapy

Volumn 35, Issue 1, 2012, Pages 78-88

  Harris, Rebecca C ^a   Chianese Bullock, Kimberly A ^a   Petroni, Gina R ^b   Schaefer, Jochen T ^c   Brill II, Louis B ^a   Molhoek, Kerrington R ^a   Deacon, Donna H ^a   Patterson, James W ^a   Slingluff Jr , Craig L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

cancer vaccines; chemokines; dendritic cells; histology; immunotherapy; melanoma; T lymphocytes

Indexed keywords

CANCER VACCINE; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MELANOMA PEPTIDE; MONTANIDE ISA 51; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; BIOPSY; DENDRITIC CELL; HIGH ENDOTHELIAL VENULE; HUMAN; HUMAN TISSUE; INJECTION SITE; MELANOMA; MICROENVIRONMENT; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VENULE;

ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CANCER VACCINES; CELL COMMUNICATION; CELL MOVEMENT; CELLULAR MICROENVIRONMENT; CYTOKINES; DENDRITIC CELLS; FORKHEAD TRANSCRIPTION FACTORS; FREUND'S ADJUVANT; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOMODULATION; INJECTIONS, INTRADERMAL; LIPIDS; MELANOMA; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE FRAGMENTS; SKIN; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84155163017     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31823731a4     Document Type: Article

References (36)

1. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. Comment in: JAMA 1994 Mar 23-30;271(12):945-6
2. Comment in: JAMA 1994 Nov 2;272(17):1327.
3. JAMA 1994;271(12):907-13.
4. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043-6053.
5. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodeplet-ing chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
6. Hodi FS, O'Day SJ, McDermott DF, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med. 2010;363:711-723.
7. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
8. Wallack MK, Sivanandham M, Balch CM, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg. 1998;187:69-77.
9. Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immunother-apy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol. 2002;20:2058-2066.
10. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19:2370-2380.
11. Schadendorf D, Nestle FO, Broecker E-B, et al. DeCOG-DC Study Group. Dacarbacine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) as first-line treatment of patients with metastatic melanoma: Results of a prospective-randomized phase III study. Abstract 7508. J Clin Oncol 2004;22(14S (July 15 Supplement, ASCO Annual Meeting Proceedings):7508.
12. Morton DL, Mozzillo N, Thompson JF, et al. MMAIT Clinical Trials Group. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25[18 S (June 20 Supplement)], abstract 8508. 2007.
13. Freund J, Thomson KJ. A simple, rapid technic of preparing water-in-oil emulsions of penicillin, drugs and biologics. Science. 1945;101:468-469.
14. Brinckerhoff LH, Kalashnikov VV, Thompson LW, et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for pep-tide vaccines. Int J Cancer. 1999;83:326-334.
15. Slingluff CL Jr., Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003;21:4016-4026.
16. Slingluff CL Jr., Petroni GR, Yamshchikov GV, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose inter-leukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol. 2004;22:4474-4485.
17. Slingluff CL Jr., Petroni GR, Chianese-Bullock KA, et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res. 2007;13:6386-6395.
18. + T cell responses to a multipeptide melanoma vaccine: Outcome of a multicenter randomized trial. Clin Cancer Res. 2009;15:7036-7044.
19. Ahlers JD, Dunlop N, Alling DW, et al. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte- macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J Immunother. 1997;158:3947-3958.
20. + T cells of two formulations of an incomplete Freund's adjuvant for multipeptide melanoma vaccines. J Immunother. 2010;33:630-638.
21. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, et al. A randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol. 2011;29:2924-2932.
22. Slingluff CL Jr., Chianese-Bullock KA, Bullock TN, et al. Immunity to melanoma antigens: from self-tolerance to immunotherapy. Adv Immunol. 2006;90:243-295.
23. Slingluff CL Jr, Petroni GR, Olson W, et al. Helper T cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol. 2008;26:4973-4980.
24. Glass G, Papin JA, Mandell JW. SIMPLE: a sequential immunoperoxidase labeling and erasing method. J Histochem Cytochem. 2009;57:899-905.
25. Drayton DL, Liao S, Mounzer RH, et al. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol. 2006;7:344-353.
26. Aloisi F, Pujol-Borrell R, Aloisi F, et al. Lymphoid neogenesis in chronic inflammatory diseases. Nat Reviews Immunol. 2006; 6:205-217.
27. Bleul CC, Fuhlbrigge RC, Casasnovas JM, et al. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. 1996;184:1101-1109.
28. Nanki T, Hayashida K, El-Gabalawy HS, et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol. 2000;165:6590-6598.
29. Voloshin I, Gelinas J, Maloney MD, et al. Proinflammatory cytokines and metalloproteases are expressed in the subacro-mial bursa in patients with rotator cuff disease. Arthroscopy. 2005;21:1076.
30. Bradfield PF, Amft N, Vernon-Wilson E, et al. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue. Arthritis Rheum. 2003;48:2472-2482.
31. Legler DF, Loetscher M, Roos RS, et al. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med. 1998;187:655-660.
32. Filipazzi P, Valenti R, Huber V, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macro-phage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25:2546-2553.
33. Wang J, Ioan-Facsinay A, van der Voort EIH, et al. Toes REM. Transient expression of FOXP3 in human activated nonregula-tory CD4+ T cells. Eur J Immunol. 2007;37:129-138.
34. Pillai V, Ortega SB, Wang CK, et al. Transient regulatory T-cells: a state attained by all activated human T cells. Clin Immunol. 2007;123:18-29.
35. Ahmadzadeh M, Felipe-Silva A, Heemskerk B, et al. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood. 2008;112:4953-4960.
36. Suffner J, Hochweller K, Kuhnle MC, et al. Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3.LuciDTR mice. J Immunol. 2010;184:1810-1820.